Sign in

Back to Explore

SinoDrugWatch

Bilingual insights into China and global drug innovation.

Latest Posts

西米普利单抗新适应症获FDA批准用于术后辅助治疗CSCC

SDW Editor · 8 Oct 2025

Libtayo® Gains FDA Approval as First Adjuvant PD-1 Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

SDW Editor · 8 Oct 2025

Zenas与诺诚健华达成逾20亿美元许可合作，获奥布替尼全球权益

SDW Editor · 8 Oct 2025

Contributors

S

SDW Editor

Creator of SinoDrugWatch